HLscience Co. Ltd (239610) - Net Assets
Based on the latest financial reports, HLscience Co. Ltd (239610) has net assets worth ₩87.36 Billion KRW (≈ $59.20 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩89.51 Billion ≈ $60.66 Million USD) and total liabilities (₩2.15 Billion ≈ $1.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 239610 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩87.36 Billion |
| % of Total Assets | 97.6% |
| Annual Growth Rate | 24.87% |
| 5-Year Change | -1.35% |
| 10-Year Change | 550.78% |
| Growth Volatility | 71.36 |
HLscience Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how HLscience Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 239610 total asset value for the complete picture of this company's asset base.
Annual Net Assets for HLscience Co. Ltd (2014–2024)
The table below shows the annual net assets of HLscience Co. Ltd from 2014 to 2024. For live valuation and market cap data, see how much is HLscience Co. Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩94.54 Billion ≈ $64.07 Million |
-7.85% |
| 2023-12-31 | ₩102.59 Billion ≈ $69.53 Million |
-1.56% |
| 2022-12-31 | ₩104.22 Billion ≈ $70.63 Million |
-2.84% |
| 2021-12-31 | ₩107.26 Billion ≈ $72.69 Million |
+11.91% |
| 2020-12-31 | ₩95.84 Billion ≈ $64.95 Million |
+18.01% |
| 2019-12-31 | ₩81.21 Billion ≈ $55.04 Million |
+28.93% |
| 2018-12-31 | ₩62.99 Billion ≈ $42.69 Million |
+18.54% |
| 2017-12-31 | ₩53.14 Billion ≈ $36.01 Million |
+5.87% |
| 2016-12-31 | ₩50.19 Billion ≈ $34.01 Million |
+245.47% |
| 2015-12-31 | ₩14.53 Billion ≈ $9.85 Million |
+41.65% |
| 2014-12-31 | ₩10.26 Billion ≈ $6.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HLscience Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 649.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩71.42 Billion | 75.55% |
| Common Stock | ₩2.70 Billion | 2.85% |
| Other Components | ₩20.42 Billion | 21.60% |
| Total Equity | ₩94.54 Billion | 100.00% |
HLscience Co. Ltd Competitors by Market Cap
The table below lists competitors of HLscience Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NTG Clarity Networks Inc.
V:NCI
|
$30.83 Million |
|
GRITEE Inc
KQ:204020
|
$30.84 Million |
|
Italian-Thai Development Public Company Limited
F:NYVF
|
$30.86 Million |
|
Xavis Co. Ltd
KQ:254120
|
$30.87 Million |
|
IT Link
PA:ALITL
|
$30.81 Million |
|
Parkson Retail Group Limited
F:P5IB
|
$30.80 Million |
|
Commerce Resources Corp.
V:CCE
|
$30.80 Million |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
$30.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HLscience Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 102,421,367,240 to 94,544,291,820, a change of -7,877,075,420 (-7.7%).
- Net loss of 7,876,510,090 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.88 Billion | -8.33% |
| Other Changes | ₩-565.33K | -0.0% |
| Total Change | ₩- | -7.69% |
Book Value vs Market Value Analysis
This analysis compares HLscience Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.48x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.96x to 0.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9291.87 | ₩8930.00 | x |
| 2017-12-31 | ₩9997.12 | ₩8930.00 | x |
| 2018-12-31 | ₩11850.85 | ₩8930.00 | x |
| 2019-12-31 | ₩15279.19 | ₩8930.00 | x |
| 2020-12-31 | ₩18257.48 | ₩8930.00 | x |
| 2021-12-31 | ₩20443.63 | ₩8930.00 | x |
| 2022-12-31 | ₩20353.28 | ₩8930.00 | x |
| 2023-12-31 | ₩20110.42 | ₩8930.00 | x |
| 2024-12-31 | ₩18563.76 | ₩8930.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HLscience Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.59%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.03x
- Recent ROE (-8.33%) is below the historical average (12.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 20.78% | 12.39% | 1.24x | 1.35x | ₩1.11 Billion |
| 2015 | 24.32% | 14.90% | 1.36x | 1.20x | ₩2.08 Billion |
| 2016 | 12.10% | 14.84% | 0.75x | 1.09x | ₩1.05 Billion |
| 2017 | 9.30% | 12.29% | 0.70x | 1.09x | ₩-373.47 Million |
| 2018 | 17.25% | 16.95% | 0.90x | 1.13x | ₩4.57 Billion |
| 2019 | 24.31% | 15.39% | 1.36x | 1.16x | ₩11.62 Billion |
| 2020 | 20.49% | 13.73% | 1.34x | 1.12x | ₩10.06 Billion |
| 2021 | 12.62% | 12.97% | 0.89x | 1.10x | ₩2.81 Billion |
| 2022 | 1.53% | 3.02% | 0.48x | 1.04x | ₩-8.83 Billion |
| 2023 | -1.34% | -5.38% | 0.24x | 1.03x | ₩-11.62 Billion |
| 2024 | -8.33% | -44.59% | 0.18x | 1.03x | ₩-17.33 Billion |
Industry Comparison
This section compares HLscience Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HLscience Co. Ltd (239610) | ₩87.36 Billion | 20.78% | 0.02x | $30.82 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About HLscience Co. Ltd
HLscience Co., Ltd. manufactures and sells health functional foods in South Korea. The company offers organic barley grassjuice powder one day, queen's pomegranate jin, Super LuzieA+ Astaxanthin, Dr. Superkhan, HL-JOINT 100 for Joint & Cartilage Premium, Dr. Green Propolis, morosil diet fit, skin master secret, enerlinger vitamin D, PS300 formulated by doctor, Skin Master P-estro, and Dr. Prebiot… Read more